Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
Viracta, a US-based developer of treatments for virus-associated malignancies that counts pharmaceutical company Salubris as an investor, completed a series D round of undisclosed size led by venture capital firm Taiwania Capital Management on Monday. Salubris joined NantKwest, Virtus Inspire Ventures, Latterell Venture Partners and Forward Ventures for a round that closed at $10.7m in February 2019 alongside $5.7m in convertible debt. It followed $59m in funding from investors including Lilly Ventures, a corporate VC vehicle for pharmaceutical firm…
